Status of work on December
AOTMiT begins work on the Ministry of Health’s orders in December:
- Remsima, infliximab in subcutaneous form, for the treatment of rheumatoid arthritis
- Remsima, infliximab in subcutaneous form, for the treatment of ankylosing spondylitis
- Remsima, infliximab in subcutaneous form, for the treatment of psoriatic arthritis
- Remsima, infliximab in subcutaneous form, for the treatment of plaque psoriasis
- Erwinase, Crisantaspasum for the treatment of lymphoblastic leukemia
The listed orders are available on the AOTMiT Public Information Bulletin.